Works matching IS 08876924 AND DT 2009 AND VI 23 AND IP 11

Results: 34

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?
Published in:
2009
By:
- Cardinaud, B.;
- Moreilhon, C.;
- Marcet, B.;
- Robbe-Sermesant, K.;
- LeBrigand, K.;
- Mari, B.;
- Eclache, V.;
- Cymbalista, F.;
- Raynaud, S.;
- Barbry, P.
Publication type:
Letter
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Published in:
2009
By:
- Gutman, D.;
- Morales, A. A.;
- Boise, L. H.
Publication type:
Letter
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
Published in:
2009
By:
- Del Giudice, I.;
- Osuji, N.;
- Dexter, T.;
- Brito-Babapulle, V.;
- Parry-Jones, N.;
- Chiaretti, S.;
- Messina, M.;
- Morgan, G.;
- Catovsky, D.;
- Matutes, E.
Publication type:
Letter
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2007, doi. 10.1038/leu.2009.140
By:
- Böttcher, S.;
- Stilgenbauer, S.;
- Busch, R.;
- Brüggemann, M.;
- Raff, T.;
- Pott, C.;
- Fischer, K.;
- Fingerle-Rowson, G.;
- Döhner, H.;
- Hallek, M.;
- Kneba, M.;
- Ritgen, M.
Publication type:
Article
Mutations of ASXL1 gene in myeloproliferative neoplasms.
Published in:
2009
By:
- Carbuccia, N.;
- Murati, A.;
- Trouplin, V.;
- Brecqueville, M.;
- Adélaïde, J.;
- Rey, J.;
- Vainchenker, W.;
- Bernard, O. A.;
- Chaffanet, M.;
- Vey, N.;
- Birnbaum, D.;
- Mozziconacci, M. J.
Publication type:
Letter
Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).
Published in:
2009
By:
- Nagel, I.;
- Bug, S.;
- Tönnies, H.;
- Ammerpohl, O.;
- Richter, J.;
- Vater, I.;
- Callet-Bauchu, E.;
- Calasanz, M. J.;
- Martinez-Climent, J. A.;
- Bastard, C.;
- Salido, M.;
- Schroers, E.;
- Martin-Subero, J. I.;
- Gesk, S.;
- Harder, L.;
- Majid, A.;
- Dyer, M. J. S.;
- Siebert, R.;
- Tönnies, H
Publication type:
Letter
IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2102, doi. 10.1038/leu.2009.139
By:
- Regis, G.;
- Icardi, L.;
- Conti, L.;
- Chiarle, R.;
- Piva, R.;
- Giovarelli, M.;
- Poli, V.;
- Novelli, F.
Publication type:
Article
Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore...if you have myeloma’.
Published in:
2009
By:
- Harvey, R. D.;
- Nettles, J.;
- Wang, B.;
- Sun, S.-Y.;
- Lonial, S.
Publication type:
Editorial
Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.
Published in:
2009
By:
- Roussou, M.;
- Tasidou, A.;
- Dimopoulos, M. A.;
- Kastritis, E.;
- Migkou, M.;
- Christoulas, D.;
- Gavriatopoulou, M.;
- Zagouri, F.;
- Matsouka, C.;
- Anagnostou, D.;
- Terpos, E.
Publication type:
Letter
Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1.
Published in:
2009
By:
- Terme, J.-M.;
- Mocquet, V.;
- Kuhlmann, A.-S.;
- Zane, L.;
- Mortreux, F.;
- Wattel, E.;
- Duc Dodon, M.;
- Jalinot, P.
Publication type:
journal article
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
Published in:
2009
By:
- Familiades, J.;
- Bousquet, M.;
- Lafage-Pochitaloff, M.;
- Béné, M-C.;
- Beldjord, K.;
- De Vos, J.;
- Dastugue, N.;
- Coyaud, E.;
- Struski, S.;
- Quelen, C.;
- Prade-Houdellier, N.;
- Dobbelstein, S.;
- Cayuela, J.-M.;
- Soulier, J.;
- Grardel, N.;
- Preudhomme, C.;
- Cavé, H.;
- Blanchet, O.;
- Lhéritier, V.;
- Delannoy, A.
Publication type:
journal article
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2139, doi. 10.1038/leu.2009.136
By:
- Colucci, S.;
- Brunetti, G.;
- Mori, G.;
- Oranger, A.;
- Centonze, M.;
- Mori, C.;
- Cantatore, F. P.;
- Tamma, R.;
- Rizzi, R.;
- Liso, V.;
- Zallone, A.;
- Grano, M.
Publication type:
Article
A robust xenotransplantation model for acute myeloid leukemia.
Published in:
2009
By:
- Sanchez, P. V.;
- Perry, R. L.;
- Sarry, J. E.;
- Perl, A. E.;
- Murphy, K.;
- Swider, C. R.;
- Bagg, A.;
- Choi, J. K.;
- Biegel, J. A.;
- Danet-Desnoyers, G.;
- Carroll, M.
Publication type:
journal article
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2118, doi. 10.1038/leu.2009.145
By:
- Plander, M.;
- Seegers, S.;
- Ugocsai, P.;
- Diermeier-Daucher, S.;
- Iványi, J.;
- Schmitz, G.;
- Hofstädter, F.;
- Schwarz, S.;
- Orsó, E.;
- Knüchel, R.;
- Brockhoff, G.
Publication type:
Article
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
Published in:
2009
By:
- Österborg, A.;
- Foà, R.;
- Bezares, R. F.;
- Dearden, C.;
- Dyer, M. J. S.;
- Geisler, C.;
- Lin, T. S.;
- Montillo, M.;
- van Oers, M. H. J.;
- Wendtner, C.-M.;
- Rai, K. R.;
- Osterborg, A;
- Foà, R
Publication type:
journal article
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2147, doi. 10.1038/leu.2009.147
By:
- Dimopoulos, M. A.;
- Chen, C.;
- Spencer, A.;
- Niesvizky, R.;
- Attal, M.;
- Stadtmauer, E. A.;
- Petrucci, M. T.;
- Yu, Z.;
- Olesnyckyj, M.;
- Zeldis, J. B.;
- Knight, R. D.;
- Weber, D. M.
Publication type:
Article
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2027, doi. 10.1038/leu.2009.148
By:
- Cortelezzi, A.;
- Pasquini, M. C.;
- Gardellini, A.;
- Gianelli, U.;
- Bossi, A.;
- Reda, G.;
- Sarina, B.;
- Musto, P.;
- Barcellini, W.;
- Neri, A.;
- Deliliers, G. L.
Publication type:
Article
Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2018, doi. 10.1038/leu.2009.144
By:
- Farfsing, A.;
- Engel, F.;
- Seiffert, M.;
- Hartmann, E.;
- Ott, G.;
- Rosenwald, A.;
- Stilgenbauer, S.;
- Döhner, H.;
- Boutros, M.;
- Lichter, P.;
- Pscherer, A.
Publication type:
Article
Imatinib mesylate causes growth plate closure in vivo.
Published in:
2009
By:
- Vandyke, K.;
- Dewar, A. L.;
- Fitter, S.;
- Menicanin, D.;
- To, L. B.;
- Hughes, T. P.;
- Zannettino, A. C. W.
Publication type:
Letter
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2034, doi. 10.1038/leu.2009.151
By:
- Mason, K. D.;
- Khaw, S. L.;
- Rayeroux, K. C.;
- Chew, E.;
- Lee, E. F.;
- Fairlie, W. D.;
- Grigg, A. P.;
- Seymour, J. F.;
- Szer, J.;
- Huang, D. C. S.;
- Roberts, A. W.
Publication type:
Article
Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).
Published in:
2009
By:
- Nishioka, C.;
- Ikezoe, T.;
- Yang, J.;
- Yokoyama, A.
Publication type:
Letter
Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells.
Published in:
2009
By:
- Shin, D. M.;
- Zuba-Surma, E. K.;
- Wu, W.;
- Ratajczak, J.;
- Wysoczynski, M.;
- Ratajczak, M. Z.;
- Kucia, M.
Publication type:
journal article
Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis.
Published in:
2009
By:
- Eberhart, K.;
- Renner, K.;
- Ritter, I.;
- Kastenberger, M.;
- Singer, K.;
- Hellerbrand, C.;
- Kreutz, M.;
- Kofler, R.;
- Oefner, P. J.
Publication type:
Letter
The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2063, doi. 10.1038/leu.2009.155
By:
- De Luca, K.;
- Frances-Duvert, V.;
- Asensio, M.-J.;
- Ihsani, R.;
- Debien, E.;
- Taillardet, M.;
- Verhoeyen, E.;
- Bella, C.;
- Lantheaume, S.;
- Genestier, L.;
- Defrance, T.
Publication type:
Article
Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.
Published in:
2009
By:
- Lee, H. M.;
- Wu, W.;
- Wysoczynski, M.;
- Liu, R.;
- Zuba-Surma, E. K.;
- Kucia, M.;
- Ratajczak, J.;
- Ratajczak, M. Z.
Publication type:
journal article
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.
Published in:
2009
By:
- Bhat, R.;
- Malinge, S.;
- Gamis, A. S.;
- Sorrell, A. D.;
- Hilden, J. M.;
- Ketterling, R. P.;
- Paietta, E.;
- Tallman, M. S.;
- Crispino, J. D.
Publication type:
commentary
The molecular characterization and clinical management of multiple myeloma in the post-genome era.
Published in:
2009
By:
- Zhou, Y.;
- Barlogie, B.;
- Shaughnessy, J. D.;
- Shaughnessy, J D Jr
Publication type:
journal article
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2129, doi. 10.1038/leu.2009.161
By:
- Eckerle, S.;
- Brune, V.;
- Döring, C.;
- Tiacci, E.;
- Bohle, V.;
- Sundström, C.;
- Kodet, R.;
- Paulli, M.;
- Falini, B.;
- Klapper, W.;
- Chaubert, A. B.;
- Willenbrock, K.;
- Metzler, D.;
- Bräuninger, A.;
- Küppers, R.;
- Hansmann, M.-L.
Publication type:
Article
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
Published in:
2009
By:
- Davies, A.;
- Jordanides, N. E.;
- Giannoudis, A.;
- Lucas, C. M.;
- Hatziieremia, S.;
- Harris, R. J.;
- Jørgensen, H. G.;
- Holyoake, T. L.;
- Pirmohamed, M.;
- Clark, R. E.;
- Mountford, J. C.;
- Jørgensen, H G
Publication type:
journal article
Harmonization of molecular monitoring of CML therapy in Europe.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 1957, doi. 10.1038/leu.2009.168
By:
- Müller, M. C.;
- Cross, N. C. P.;
- Erben, P.;
- Schenk, T.;
- Hanfstein, B.;
- Ernst, T.;
- Hehlmann, R.;
- Branford, S.;
- Saglio, G.;
- Hochhaus, A.
Publication type:
Article
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Published in:
2009
By:
- Hasegawa, H.;
- Yamada, Y.;
- Iha, H.;
- Tsukasaki, K.;
- Nagai, K.;
- Atogami, S.;
- Sugahara, K.;
- Tsuruda, K.;
- Ishizaki, A.;
- Kamihira, S.
Publication type:
journal article
Proteasome inhibitors in the treatment of multiple myeloma.
Published in:
2009
By:
- Shah, J. J.;
- Orlowski, R. Z.
Publication type:
journal article
Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population.
Published in:
Leukemia (08876924), 2009, v. 23, n. 11, p. 2075, doi. 10.1038/leu.2009.178
By:
- Weston-Bell, N.;
- Townsend, M.;
- Di Genova, G.;
- Forconi, F.;
- Sahota, S. S.
Publication type:
Article
HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation
Published in:
2009
By:
- Akl, H;
- Badran, B M;
- El Zein, N;
- Bex, F;
- Sotiriou, C;
- Willard-Gallo, K E;
- Burny, A;
- Martiat, P
Publication type:
Correction Notice

Works matching IS 08876924 AND DT 2009 AND VI 23 AND IP 11

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.

Mutations of ASXL1 gene in myeloproliferative neoplasms.

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore...if you have myeloma’.

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1.

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.

A robust xenotransplantation model for acute myeloid leukemia.

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.

Imatinib mesylate causes growth plate closure in vivo.

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).

Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells.

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis.

The TLR1/2 agonist PAM<sub>3</sub>CSK<sub>4</sub> instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

Harmonization of molecular monitoring of CML therapy in Europe.

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.

Proteasome inhibitors in the treatment of multiple myeloma.

Defining origins of malignant B cells: a new circulating normal human IgM<sup>+</sup>D<sup>+</sup> B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population.

HTLV-I infection of WE17/10 CD4<sup>+</sup> cell line leads to progressive alteration of Ca<sup>2+</sup> influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation